What are the treatment options for dry eye syndrome?

Managing dry eye syndrome involves a multifaceted, individualized approach aimed at restoring tear film stability, reducing ocular surface inflammation, and addressing underlying contributing factors. First-line therapy typically includes preservative-free artificial tears used as needed to supplement inadequate or poor-quality tear production. For patients with moderate to severe disease, prescription anti-inflammatory agents—such as topical cyclosporine A (0.05% or 0.1%) or lifitegrast 5% ophthalmic solution—are FDA-approved to target the chronic inflammatory component central to dry eye pathophysiology. Punctal occlusion with temporary or permanent silicone plugs may be considered to conserve endogenous tears in cases of aqueous-deficient dry eye. Additional evidence-based interventions include warm compresses and lid hygiene to manage meibomian gland dysfunction—a leading cause of evaporative dry eye—as well as oral omega-3 fatty acid supplementation, which has demonstrated modest but clinically meaningful improvements in tear film stability and symptom scores in randomized controlled trials. Environmental modifications (e.g., humidification, minimizing screen time with adherence to the 20-20-20 rule, avoiding direct airflow from fans or HVAC vents) and behavioral adjustments (e.g., conscious blinking during visual tasks) are essential adjunctive strategies. In refractory cases, advanced options such as autologous serum eye drops, intense pulsed light (IPL) therapy for meibomian gland dysfunction, or short-term topical corticosteroids under close supervision may be warranted. A thorough evaluation—including tear breakup time, Schirmer testing, ocular surface staining (e.g., fluorescein, lissamine green), and meibomian gland assessment—is critical before initiating treatment to guide appropriate therapeutic selection.